Adding pancreatic panniculitis to the panel of skin lesions associated with triple therapy of chronic hepatitis C

摘要

Dermatological side effects are a major concern in peginterferon (PeglFN)-based treatments of hepatitis C virus (HCV) infection, with eczematous dermatitis, xerosis, generalized pruritus and exacerbation of underlying skin disorders as prominent examples. The recent registration of the protease inhibitor tela-previr in combination with PeglFN and ribavirin (RBV) is expected to significantly increase the rate and severity of dermatological side effects by causing a rash in more than 50% of patients. Thus, early recognition of skin abnormalities will be crucial to assure their effective treatment, avoid premature cessation of therapy, and to allow for an optimal treatment outcome (1).